About the Authors

Adrienne Verhoef

To whom correspondence should be addressed. E-mail: a.verhoef@imperial.ac.uk

Affiliation Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, London, United Kingdom

Clare Alexander

Affiliation Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, London, United Kingdom

A. Barry Kay

Affiliation Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, London, United Kingdom

Mark Larché

Affiliation Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, London, United Kingdom

Competing Interests

ML and ABK have current research funding from Powderject Pharmaceuticals (currently owned by Chiron Vaccines). Powderject Pharmaceuticals was, until its acquisition by Chiron, developing peptide vaccines, based on those described herein, for commercial purposes. ML is a named inventor on three families of patent applications relating to peptide immunotherapy and peptide immunotherapeutics; ABK is a named inventor on two of these families of patent applications. ML and ABK were formerly paid consultants to Powderject Pharmaceuticals and former stockholders. ML and ABK were formerly stockholders in Circassia, a company that they founded.

Author Contributions

AV, ABK, and ML designed the study. AV, CA, ABK, and ML performed the experiments. AV, ABK, and ML contributed to writing the paper.